Flashcards in Lung Deck (452)
Pulmonary Langerhans'-cell histiocytosis: Histology (4).
Stellate or Medusa-head nodules centered on bronchioles.
Nodules consist of Langerhans' cells (grooved nuclei), eosinophils, lymphocytes, plasma cells.
Nodules may invade vessels.
Progression from cellular nodules to fibrotic scars.
Pulmonary Langerhans'-cell histiocytosis: Associated histologic finding.
Pulmonary Langerhans'-cell histiocytosis: Expressed cytokines (2).
Langerhans' cells: Immunohistochemistry.
Positive: S-100, CD1a, Langerin.
Reactive eosinophilic pleuritis:
B. Eosinophils mixed with proliferating mesothelial cells and mononuclear cells.
Post-transplantation lymphoproliferative disorder: Definition.
Abnormal lymphocytic proliferation (benign or malignant) occurring during immunosuppression and often involving the transplanted organ.
Post-transplantation lymphoproliferative disorder: Origin of proliferating cells.
Bone marrow: The donor.
Solid organs: The recipient.
Post-transplantation lymphoproliferative disorder: Timing.
Occurs 1 month to 4 years after the transplantation.
Post-transplantation lymphoproliferative disorder: Viral association.
Post-transplantation lymphoproliferative disorder in the lung: Types.
Polymorphic lymphoproliferative disorder.
Malignant lymphoma or multiple myeloma.
PTLD of the lung: Association of type with age.
Plasmacytic hyperplasia is the most common type in children and young adults.
PTLD of the lung: Histology of plasmacytic hyperplasia.
Proliferation of small polyclonal T and B lymphocytes, plasma cells, occasional immunoblasts.
Preserved pulmonary architecture.
PTLD of the lung: Histology of polymorphic lymphoproliferative disorder.
Clonal lymphocytes, plasmacytoid cells; immunoblasts that may resemble Reed-Sternberg cells.
Distorted pulmonary architecture.
PTLD of the lung: Most common type of lymphoma.
Diffuse large B-cell lymphoma.
Post-transplantation lymphoproliferative disorder: Treatment.
Reduction in immunosuppression during the first year after transplantation.
Malignant mesothelioma: Prognosis (2).
Death in <1 year; a few months later for epithelioid mesothelioma.
Malignant mesothelioma: Relation to smoking.
Smoking does not increase the risk of mesothelioma.
Smoking + asbestos = greatly increased risk for lung carcinoma.
Malignant mesothelioma: Variants.
Epithelioid mesothelioma: Cytology.
Nuclei: Round, vesicular; large nucleolus.
Epithelioid mesothelioma: Histology.
Grows in tubules, papillae, glands or acini, solid sheets, or a combination of patterns.
A. A collagenous subtype of sarcomatoid mesothelioma.
B. Makes up about 10% of malignant mesothelioma.
Biphasic mesothelioma: Criterion.
The tumor must be at least 10% epithelioid and at least 10% sarcomatoid.
Malignant mesothelioma: Most common variant.
Malignant mesothelioma: "Specific" markers (4).
Malignant mesothelioma: Nonspecific markers (2).
Malignant mesothelioma: Mutation.
Homozygous deletion of CDKN2A/ARF at 9p21.
Malignant mesothelioma: Best immunohistochemical marker and its interpretation.
- Stains cytoplasm of all mesothelial cells.
- Stains nuclei of malignant mesothelioma.
Malignant mesothelioma vs. reactive mesothelial hyperplasia: Histology.
Reactive mesothelial hyperplasia does not invade the parietal pleural fat.
Malignant mesothelioma vs. reactive mesothelial hyperplasia: Immunohistochemistry (4).
Reactive mesothelial hyperplasia: Cytoplasmic desmin.
Malignant mesothelioma: Linear EMA, strong p53, GLUT1.